Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy for advanced cancers enters human testing

NCT ID NCT07260305

Recruiting now Disease control Sponsor: Kangabio AUSTRALIA LTD PTY Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 15 times

Summary

This early-phase study tests a new drug called KGX101, given alone or with envafolimab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 57 participants will receive the drug every 3 weeks and have regular checkups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Fudan university Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shanghai Chest Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200433, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC SOLID TUMORS